

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : G01N 33/543, 33/546, 549/571 C12N 9/96	A1	(11) International Publication Number: WO 87/ 03692 (43) International Publication Date: 18 June 1987 (18.06.87)
(21) International Application Number: PCT/US86/02592 (22) International Filing Date: 2 December 1986 (02.12.86) (31) Priority Application Number: 804,059 (32) Priority Date: 3 December 1985 (03.12.85) (33) Priority Country: US (71) Applicant: ADVANCED POLYMER SYSTEMS, INC. [US/US]; 3696C Haven Avenue, Redwood City, CA 94063 (US). (72) Inventor: YABUSAKI, Kenichi, Ken ; 510 Carmel Avenue, Albany, CA 94706 (US). (74) Agents: CIOTTI, Thomas, E. et al.; Ciotti & Murashige, 545 Middlefield Road, Suite 200, Menlo Park, CA 94025-3471 (US).		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent). Published <i>With international search report.</i>
(54) Title: REAGINIC TEST FOR SYPHILIS (57) Abstract A reaginic agglutination test for syphilis-associated antibodies. The test uses an antigen reagent that comprises a buffered aqueous suspension of cardiolipin antigen ionically coupled to latex particles via a polypeptide bridge. Positive sera react with the antigen reagent and yield an agglutination pattern characterized by medium to large aggregates. Negative sera yield no agglutinated particles.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

REAGINIC TEST FOR SYPHILISDescription5 Technical Field

This invention is in the field of immunological testing. More particularly, it concerns a screening test for syphilis-associated antibodies that employs cardiolipin antigen ionically coupled to latex particles
10 via a polypeptide bridge.

Background Art

Two main categories of serologic tests for syphilis are available: tests for reaginic antibody and
15 tests for treponemal antibody. Reaginic tests use cardiolipin as antigen and are normally used for screening because they are sensitive and fast, but lack a high degree of specificity. The treponemal tests use treponemal antigens and, because they involve a more rigorous
20 and demanding procedure, are used principally as confirmatory tests on samples that are positive in the reaginic test.

Commercial reaginic tests are divided into two categories: microscopic and macroscopic. The microscopic tests are the Venereal Disease Research Laboratory (VDRL) slide and the Unheated Serum Reagin (USR) tests. The VDRL antigen consists of an ethanol solution of 0.03% cardiolipin, 0.9% cholesterol, and 0.21% lecithin. VDRL antigen is added to buffered saline containing 0.05% formaldehyde to form a suspension of VDRL antigen. The antigen suspension is then added to heat-treated (56°C for 30 min) serum. If the serum contains reaginic antibodies, they will combine with the antigen to form a flocculant that is visible on microscopic
25
30

-2-

examination. Lack of flocculation is a negative reaction. The USR is a flocculation test similar to the VDRL. It differs from the VDRL in that it uses a VDRL antigen suspension stabilized with ethylene diamine tetraacetic acid with choline chloride added and does not require serum heating.

There are several macroscopic reagin tests. Most of them involve a modified VDRL antigen that provides a macroscopically visible antigen-antibody reaction product. Examples of such modifiers are charcoal particles and dyes such as Sudan Black B and toluidine red.

Uyeda, C.T., Am J Clin Path (1963) 40:329-333, describes a macroscopic reagin test that uses VDRL antigen adsorbed onto latex particles. Both unheated and heated sera were tested, but the results with unheated sera were characterized as being occasionally inconsistent.

Some treponemal tests use treponemal antigen immobilized on a carrier. For instance, the Treponema pallidum hemagglutination test (TPHA) uses red blood cells as a carrier with treponemes adsorbed on their surfaces. Also, U.S. 4,272,510 describes an enzyme immunoassay for antibodies to Treponema pallidum that uses treponemal antigen immobilized on ferrous metal beads.

U.S. 4,181,636 suggests that various "immunologically active materials", including Treponema pallidum, may be covalently bound to carboxylated latex particles via a coupling agent such as a carbodiimide. U.S. 4,264,766 suggests a similar system in which antigen is bound to the carboxylated latex via a polysaccharide.

Disclosure of the Invention

The present invention provides a test for syphilis-associated antibodies that combines the sensitivity (lack of false-negatives), speed, and simplicity of existing reagin tests with the advantages of not requiring use of heat inactivated serum and being useful for testing plasma and cerebrospinal fluid as well as serum. It is also more sensitive than the VDRL test.

A critical and novel antigen reagent is the cornerstone of the test. It comprises a stable aqueous suspension of cardiolipin antigen ionically coupled to latex particles via a polypeptide bridge. This reagent is used in a flocculation or agglutination type assay that includes the following steps: (1) incubating a test sample suspected of containing syphilis-associated antibodies with the antigen reagent under conditions that permit reaction between any such antibody in the sample and the cardiolipin antigen component of the reagent, and (2) determining whether an agglomerate or flocculant has formed.

The reagent will normally be sold as part of a kit for conducting the above-described assay. The kit comprises in packaged combination: (a) a first container that contains the antigen reagent; (b) a second container that contains a negative control sample that does not react with the antigen reagent; and (c) a third container that contains a positive control sample that reacts with the antigen reagent and forms a visible flocculant or agglomerated reaction product. The kit will also typically contain a suitable buffer for diluting samples and instructions for carrying out the test.

Modes for Carrying Out the Invention

The test sample may be serum, plasma, or cerebrospinal fluid. These test samples may be obtained by conventional collection and processing procedures. In the case of serum, blood is obtained by venipuncture, allowed to clot, and serum is removed. Serum from a person infected with Treponema pallidum contains syphilitic reagin (a mixture of antibodies formed by the host in response to lipoidal material released from damaged host cells early in the infection that react with sensitized cardiolipin) and specific antibodies to treponemal antigen. Syphilitic reagin is sometimes referred to herein as "syphilis-associated antibodies".

The antigen reagent of the invention is made by ionically coupling cardiolipin antigen to latex particles via a polypeptide bridge. Preferably, a positively charged polypeptide is first bound to latex particles either by passive adsorption or chemical (covalent or ionic) bonds. In passive adsorption the latex may be neutral, carboxylated, or amino-modified whereas in chemical bonding the surface of the latex will be modified with coupling agents such as carbodiimides, in a manner that permits chemical bonding between the polypeptide bridging agent and the surface of the latex.

The positively charged polypeptide may be a homopolymer, such as a polycationic polyamino acid (e.g., polylysine, polyarginine) or composed of varying amino acids, such as methylated serum albumin. Correlatively, the polypeptide may be composed solely of amino acids or include various substituents such as sugar moieties, acyl groups, and the like. The weight average molecular weight of the polypeptide will typically be below about 500,000, preferably below about 100,000.

The particle size of the latex will usually be in the range of 0.1 to 15 microns, more usually 0.1 to 7 microns. A preferred latex has a particle size of 0.4 to 0.8 microns. Neutral and modified latexes for use in making the antigen complex are available commercially.

The latex particles are contacted with an aqueous solution of the polypeptide at a particle concentration that does not result in very large particle aggregates. In the case of the particles described in the examples, *infra*, a particle concentration in the final volume of about 4 mg/ml was found to be optimum. A saturation concentration of polypeptide in the solution is preferred.

The cardiolipin antigen that is coupled to the latex is in the form of an ethanolic solution of cardiolipin (a diphosphatidylglycerol purified from beef heart) combined with cholesterol and lecithin or other sensitizing agents that enable cardiolipin to react with syphilitic reagin. The ethanolic solution of cardiolipin and lecithin and cholesterol will contain cardiolipin in the range of approximately 0.01 to 5 mg/ml, more usually 0.1 to 1 mg/ml, and most preferably 0.2 to 0.5 mg/ml, and lecithins (from hen egg yolk, soybean, or synthetic) in the range of approximately 0.04 to 12 mg/ml, more usually 0.5 to 4 mg/ml, and most preferably approximately 1.5 to 2.5 mg/ml, and cholesterol in the range of approximately 0.5 to 13 mg/ml, usually 5 to 11 mg/ml, and preferably 8 to 9 mg/ml. VDRL antigen (described above) is preferred.

The resulting latex particle-polypeptide-cardiolipin antigen complex is suspended in an aqueous medium buffered to a pH in the range of 5-10, usually 5.5 to 8.0, and preferably 6.0 to 7.0. The concentration of complex in the medium will be in the range of

about 0.01 to 4 mg/ml, usually 0.1 to 2 mg/ml, and preferably 0.3 to 0.9 mg/ml. Various buffers may be used such as Tris, glycine, and phosphate. Phosphate is preferred. The concentration of buffer will generally be in the range of approximately 0.0001 to 0.05 M, more usually in the range of approximately 0.00075 to 0.003 M. The buffer will contain a salt such as sodium chloride. The sodium chloride concentration in the buffer will generally be in the range of approximately 0.01 to 0.5 M, more usually in the range of approximately 0.05 to 0.2 M, and preferably approximately 0.16 to 0.18 M.

Other additives may also be in the buffer medium which are employed for preserving or protecting individual components or reagents or for aiding the performance characteristics of the test. Particularly, formaldehyde can be employed in amounts of approximately 0.01 to 0.5 volume percent, more usually approximately 0.02 to 0.1 volume percent, and preferably approximately 0.04 to 0.06 volume percent. Ethylenediaminetetraacetic acid (EDTA) can be employed in amounts of approximately 0.1 to 1.0 volume percent, more usually approximately 0.2 to 0.7 volume percent and preferably approximately 0.3 to 0.6 volume percent. Choline chloride can be employed in amounts of approximately 2.5 to 15 volume percent, more usually approximately 5 to 13 volume percent and preferably approximately 8 to 11 volume percent. Sodium azide can be employed in amounts of approximately 0.005 to 0.1 volume percent. Thimerosal can be employed in amounts of approximately 0.005 to 0.1 volume percent.

Dyes may be incorporated into the latex particles and/or cardiolipin antigen to facilitate visualization of the agglomerate in the reading phase of the test. If a dye is incorporated into the cardiolipin, it should be lipophilic so that it does not leach into the

-7-

aqueous phase. Examples of such dyes are Sudan black and Nile red.

The invention test is a two-step procedure in which the test sample is first incubated with the antigen reagent. The incubation may be carried out in conventional agglutination slides or Brewers cards with 18 mm circles under conditions that favor antigen-antibody binding (essentially physiological pH, temperature, and ionic strength). The mixture is agitated gently to promote reaction (binding) between any syphilis-associated antibodies in the test serum and the antigen component of the antigen reagent. Relatively short incubation periods on the order of 4 to 12 minutes are sufficient. Longer times may be used for convenience. Negative and positive control samples are run in parallel with test sample(s) for comparison purposes.

After the incubation step, the results of the test may be read visually by placing the slide on a slide viewer and examining the contents of the slide wells for agglutination pattern under indirect light. A negative pattern shows no agglutinated particles. A weakly positive pattern is characterized by the distinct presence of slightly grainy to small agglutinated particles. A positive pattern is scored by the presence of medium to large agglutinated particles.

The invention is further illustrated by the following examples. These examples are not intended to limit the invention in any manner.

ExamplesA. Preparation of Methylated Bovine Serum Albumin-Carboxylated Latex

5 To approximately 86 mg of carboxylated latex particles (0.4-0.6 microns) suspended in 1 ml of distilled deionized water is added 5 ml of a methylated bovine serum albumin solution at 4.1 mg/ml in 0.25 Molar glycine-buffered saline followed immediately by the
10 addition of 15.5 ml of 0.25 Molar glycine-buffered saline. The entire mixture is gently stirred for 15 min. then placed in a water bath set at $37 \pm 1^\circ\text{C}$ for 2 hr. then placed at 4°C overnight. The entire suspension is then centrifuged at 10,000 rpm in a microcentrifuge for
15 10 min or at full speed on table top clinical centrifuge for 10-15 min to sediment the methylated bovine serum albumin-adsorbed latex particles. The supernatant is carefully removed and the pellet is resuspended in a phosphate-buffered saline pH 6.0 and recentrifuged at
20 10,000 rpm for 10 min or at full speed on table top clinical centrifuge for 10-15 min. The supernatant is carefully removed and the resultant pellet of methylated bovine serum albumin-adsorbed carboxylated latex particles resuspended in phosphate-buffered saline, pH 6.0.
25 and brought to a final volume of approximately 10 ml. This suspension of particles constituted a stock suspension from which subsequent reagents were prepared.

30 B. Preparation of Methylated Bovine Serum Albumin Carboxylated Latex Cardiolipin Antigen Reagent

To approximately 2.15 mg of methylated bovine serum albumin carboxylated latex particles suspended in 0.4 ml of phosphate-buffered saline, pH 6.0, and contained in a 25 ml capacity cylindrical vial is added.

-9-

dropwise with gentle shaking of the vial, 0.5 ml of an ethanolic solution consisting of approximately 0.03% cardiolipin, 0.21% lecithin, and 0.9% cholesterol. After the final drop of the ethanolic cardiolipin/lecithin/cholesterol solution is added, 4.1 ml of phosphate-buffered saline, pH 6.0, is added to the milky white suspension and the entire suspension gently shaken in a rotary motion for 30 sec. The resultant methylated bovine serum albumin carboxylated latex cardiolipin antigen reagent is stored at 4°C.

C. Preparation of Poly-DL-Lysine Carboxylated Latex

To approximately 8.6 mg of carboxylated latex particles suspended in 1.8 ml of 0.25 M glycine buffered saline, pH 8.2, is added 0.1 ml of a poly-DL-lysine (M.W. average 57,000) at 10 mg/ml in distilled water. The suspension is gently stirred for 15 min at room temperature, then placed in a 37±1°C water bath for 2 hr followed by overnight incubation at 4°C. The poly-DL-lysine adsorbed carboxylated latex particles are centrifuged at 10,000 rpm in a microcentrifuge for 10 min and the resultant pellet resuspended in phosphate-buffered saline, pH 6.0, to a final latex particle concentration of approximately 16 mg/ml.

D. Preparation of Poly-DL-Lysine Carboxylated Latex Cardiolipin Antigen Reagent

To approximately 2.15 mg of poly-DL-lysine carboxylated latex particles suspended in 0.4 ml of phosphate buffered saline, pH 6.0, and contained in a 25 ml capacity cylindrical vial is added, dropwise with gentle shaking of the vial, 0.5 ml of an ethanolic solution consisting of approximately 0.03% cardiolipin, 0.21% lecithin, and 0.9% cholesterol. After the final drop of

-10-

the ethanolic cardiolipin/lecithin/cholesterol solution is added, 4.1 ml of phosphate-buffered saline, pH 6.0, is added to the milky white suspension and the entire suspension gently shaken in a rotary motion for 30 sec.

5 The resultant poly-DL-lysine carboxylated latex cardiolipin reagent is stored at 4°C.

E. Preparation of Sudan Black B Carboxylated Latex Particles

10 To approximately 86 mg of carboxylated latex particles suspended in 1 ml of distilled water and placed under magnetic stirring is added dropwise 0.4 ml of an ethanolic solution of Sudan Black B at 2 mg/ml. The suspension is allowed to stir at room temperature

15 for 2 hr, then the suspension is centrifuged at 10,000 rpm for 30 min in a microcentrifuge. The resultant pellet is resuspended in phosphate-buffered saline, pH 6.0, and recentrifuged as described above. This step is repeated until the supernatant is clear and free of visible dye.

20

F. Preparation of Methylated Bovine Serum Albumin Sudan Black B Carboxylated Latex Particles

To approximately 17 mg of Sudan Black B carboxylated latex suspended in 0.2 ml of deionized distilled water is added 1 ml of a methylated bovine serum albumin solution at 4.1 mg/ml in 0.25 M glycine-buffered saline, pH 8.2 followed immediately by the addition of 3.05 ml of 0.25 Molar glycine-buffered saline. After

25 gentle mixing the suspension is allowed to incubate at 37±1°C for 2 hr followed by an overnight incubation at 4°C. The suspension is centrifuged at 10,000 rpm in a microcentrifuge for 10 min and the resultant pellet resuspended in phosphate-buffered saline, pH 6.0, to a

30

-11-

final latex particle concentration of approximately 17 mg/ml. The resultant methylated bovine serum albumin Sudan Black B carboxylated latex particle suspension is stored at 4°C.

5

G. Preparation of a Colored Methylated Bovine Serum
Albumin Carboxylated Latex Cardioliipin Reagent

To approximately 2.15 mg of methylated bovine serum albumin carboxylated latex particles or 2.15 mg of
10 methylated bovine serum albumin Sudan Black B carboxylated latex particles suspended in 0.4 ml of phosphate-buffered saline, pH 6.0, and contained in a 25 ml capacity cylindrical vial is added, dropwise with gentle shaking of the vial, 0.5 ml of an ethanolic solution
15 consisting of 0.03% cardioliipin, 0.21% lecithin, 0.9% cholesterol, and 0.07% Sudan Black B. after the final drop of the ethanolic cardioliipin/lecithin/cholesterol/Sudan Black B solution is added, 4.1 ml of phosphate-buffered saline, pH 6.0, is added to the dark bluish
20 suspension and the entire suspension gently shaken in a rotary motion for 30 sec then left to stand at 4°C for 18-24 hr. The entire suspension is mixed thoroughly and centrifuged at full speed in a table top clinical centrifuge for 10 min. After carefully decanting the supernatant, the resultant pellet is resuspended to the
25 approximate original volume with phosphate-buffered saline, pH 6.0. The resultant dyed methylated bovine serum albumin carboxylated latex cardioliipin antigen reagent provides an antigen reagent which can be used to
30 detect reaginic antibodies in serum, plasma, or spinal fluid or dilutions of serum, plasma, or spinal fluid by carrying out the antigen antibody reaction on, for example, a Brewer diagnostic 18 mm circle card. A positive test for reagin antibodies in serum or plasma or spinal

-12-

fluid is indicated by blue agglutinated particles viewed against the white background of the card.

H. Test Procedure for Detecting Reaginic Antibodies in

5 Unheated Serum

Approximately 0.1 ml of unheated serum is pipetted into a well of a plastic serological rotator slide measuring 0.2 x 5 x 7.5 cm containing 15 wells measuring 15 mm in diameter and 1 mm in depth. Then approximately 0.02 ml of methylated bovine serum albumin carboxylated latex cardioplipin antigen reagent is added to the serum sample. The slide is placed on the platform of a serological rotator and rotated at a constant speed of, for example, approximately 180 revolutions per minute for approximately four minutes. The slide is placed on the glass platform of a Hyperion Viewer with magnifier and examined under indirect light. A similar procedure is employed for testing cerebrospinal fluid.

20 I. Quantitative Reaginic Antibody Test

Prepare unheated serum, plasma, or cerebrospinal fluids as follows:

- a. Pipette 0.2 ml of phosphate-buffered saline, pH 6.0, into each of five or more test tubes.
- 25 b. Add 0.2 ml of unheated serum, plasma, or spinal fluid to tube one, mix well, and transfer 0.2 ml to tube two.
- c. Continue mixing and transferring 0.2 ml from one tube to the next until the last tube is reached. The respective dilution should be 1:2, 1:4, 1:8, 1:16, 1:32, etc.
- 30

Test each serum, plasma, or spinal fluid dilution and undiluted serum, plasma, or spinal fluid as de-

-13-

scribed under H. "T st Procedure for Detecting Reaginic Antibodies in Unheated Serum".

The following table presents data on tests of clinical sera of known reactivity using the invention test and the VDRL.

	Sample No.	VDRL Dilution							Invention Dilution							
		0	1:2	1:4	1:8	1:16	1:32	1:64	0	1:2	1:4	1:8	1:16	1:32	1:64	1:128
10	3392	N	N	N					N	N	N					
	94	R	R	R	W	N	N		R	R	R	W	N	N		
	3403	W	N	N					W	N	N					
	3567	R	R	R	R	W	N	N	R	R	R	R	W	N		
	69	W	N	N					W	W	W	N	N			
	90	W	N	N					N	N	N					
15	3601	R	N	N					W	N	N					
	21	R	W	N					W	N	N					
	22	N	N	N					N	N	N					
	26	W	N	N					W	N	N					
	27	W	N	N					N	N	N					
	31	R	R	R	R	W	N		R	R	R	R	W	N	N	
20	40	R	W	N					R	R	W	N	N	N		
	43	W	N	N					N	N	N					
	82	N	N	N					N	N	N					
	83	N	N	N					N	N	N					
	85	R	R	W	N	N			R	R	W	N	N	N		
	3720	R	R	R	R	W	N		R	R	R	R	R	W	N	N
25	42	N	N	N					N	N	N					
	45	R	R	R	W	N			R	R	R	R	W	N		
	50	W	N	N					N	N	N					
	55	R	R	R	W	N	N		R	R	R	R	N	N		
	64	R	R	R	W	N	N		R	R	R	W	N	N		
	3769	W	N	N					N	N	N					
30	97	N	N	N					N	N	N					
	98	N	N	N					N	N	N					
	3827	R	W	N					R	W	N	N	N	N		
	34	R	R	R	R	R	W	N	R	R	R	R	R	W	N	

N=nonreactive, W=weakly reactive, R=strong reactive

-14-

Modifications of the above-described modes for carrying out the invention that are obvious to those of skill in the fields of immunological testing, medicine, and related fields are intended to be within the scope of the following claims.

10

15

20

25

30

Claims

1. An antigen reagent for use in a reaginic
5 test for syphilis comprising an aqueous suspension of
cardiolipin antigen ionically coupled to latex particles
via a polypeptide bridge.
2. The reagent of claim 1 wherein the latex
10 particles are neutral or modified to have charged or
reactive surface moieties.
3. The reagent of claim 1 wherein the particle
size of the latex is in the range of 0.1 to 7 microns.
15
4. The reagent of claim 1 wherein the particle
size of the latex is in the range of 0.4 to 0.8 microns.
5. The reagent of claim 1 wherein the poly-
20 peptide is a polycationic polyamino acid or methylated
serum albumin.
6. The reagent of claim 1 wherein the polypep-
tide is polylysine or methylated serum albumin.
25
7. The reagent of claim 1 wherein the cardio-
lipin antigen is VDRL antigen.
8. The reagent of claim 1 wherein the aqueous
30 suspension is buffered to a pH in the range of 5-10.
9. The reagent of claim 1 wherein the aqueous
suspension is buffered at a pH of 6.0 to 7.0.

-16-

10. The reagent of claim 1 wherein the particle size of the latex is in the range of 0.4 to 0.8 microns, the latex is a carboxylated latex, the polypeptide bridge is a methylated serum albumin or polylysine bridge, the cardiolipin antigen is VDRL antigen, the suspension is buffered to a pH of 6.0 to 6.5, and the concentration of cardiolipin antigen ionically coupled to latex particles via a polypeptide bridge in the suspension is 0.3 to 0.9 mg/ml.

10

11. A reagenic test for syphilis-associated antibodies comprising:

15 (a) incubating a sample suspected of containing said antibodies with the antigen reagent of claim 1 under conditions that permit binding between said antibodies and antigen in said antigen reagent; and

(b) determining whether the antigen in said antigen reagent has agglutinated.

20

12. A reagenic test for syphilis-associated antibodies comprising:

25 (a) incubating a sample suspected of containing said antibodies with the antigen reagent of claim 5 under conditions that permit binding between said antibodies and antigen in said antigen reagent; and

(b) determining whether the antigen reagent has agglutinated.

30 13. A test for syphilis-associated antibodies comprising:

(a) incubating a sample suspected of containing said antibodies with the antigen reagent of claim 6 under conditions that permit binding between said antibodies and antigen in said antigen reagent; and

-17-

(b) determining whether the antigen reagent has agglutinated.

14. A test for syphilis-associated antibodies
5 comprising:

(a) incubating a sample suspected of containing said antibodies with the antigen reagent of claim 7 under conditions that permit binding between said antibodies and antigen in said antigen reagent; and

10 (b) determining whether the antigen reagent has agglutinated.

15 15. A test for syphilis-associated antibodies comprising:

(a) incubating a sample suspected of containing said antibodies with the antigen reagent of claim 8 under conditions that permit binding between said antibodies and antigen in said antigen reagent; and

20 (b) determining whether the antigen reagent has agglutinated.

16. A test for syphilis-associated antibodies comprising:

25 (a) incubating a sample suspected of containing said antibodies with the antigen reagent of claim 10 under conditions that permit binding between said antibodies and antigen in said antigen reagent; and

(b) determining whether the antigen reagent has agglutinated.

30

17. A kit for conducting a test for syphilis-associated antibodies comprising, in packaged combination:

-18-

(a) a first container containing the antigen reagent of claim 1;

(b) a second container containing a negative control sample that does not react with the antigen reagent; and

(c) a third container containing a positive control sample that reacts with the antigen reagent.

18. A kit for conducting a test for syphilis-associated antibodies comprising, in packaged combination:

(a) a first container containing the antigen reagent of claim 5;

(b) a second container containing a negative control sample that does not react with the antigen reagent; and

(c) a third container containing a positive control sample that reacts with the antigen reagent.

19. A kit for conducting a test for syphilis-associated antibodies comprising, in packaged combination:

(a) a first container containing the antigen reagent of claim 6;

(b) a second container containing a negative control sample that does not react with the antigen reagent; and

(c) a third container containing a positive control sample that reacts with the antigen reagent.

20. A kit for conducting a test for syphilis-associated antibodies comprising, in packaged combination:

-19-

(a) a first container containing the antigen reagent of claim 7;

(b) a second container containing a negative control sample that does not react with the antigen reagent; and

(c) a third container containing a positive control sample that reacts with the antigen reagent.

21. A kit for conducting a test for syphilis-associated antibodies comprising, in packaged combination:

(a) a first container containing the antigen reagent of claim 8;

(b) a second container containing a negative control sample that does not react with the antigen reagent; and

(c) a third container containing a positive control sample that reacts with the antigen reagent.

22. A kit for conducting a test for syphilis-associated antibodies comprising, in packaged combination:

(a) a first container containing the antigen reagent of claim 10;

(b) a second container containing a negative control sample that does not react with the antigen reagent; and

(c) a third container containing a positive control sample that reacts with the antigen reagent.

30

INTERNATIONAL SEARCH REPORT

International Application No **PCT/US86/02592**

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ³ According to International Patent Classification (IPC) or to both National Classification and IPC U.S. Cl. 435/5,7,188; 436/511, 518, 532, 533, 534 IPC 4 G01N 33/543, 546, 549/571; C12N 9/96						
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched ⁴</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">U.S.</td> <td style="padding: 5px;">435/5,7,188; 436/511, 518, 532, 533, 534</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁶</div>			Classification System	Classification Symbols	U.S.	435/5,7,188; 436/511, 518, 532, 533, 534
Classification System	Classification Symbols					
U.S.	435/5,7,188; 436/511, 518, 532, 533, 534					
STN INTERNATIONAL-FILE CA DIALOG INFORMATION SERVICES - FILE BIOSIS (5,55,255)						
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴						
Category ⁸	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸				
Y	U.S., A, 3,564,089 (SANDRA JEAN KIDDY) 16 February 1971 (16.02.71) See Abstract.	1-5,7-12, 14-18, 20-22				
Y,P	U.S., A, 4,572,901 (CHILDRENS HOSPITAL MEDICAL CENTER OF NORTHERN CALIFORNIA) 25 February 1986 (25.02.86). See Abstract and column 2, lines 36-41 and 54-68.	1-5,7-12, 14-18, 20-22				
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>⁹ Special categories of cited documents: ¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>						
IV. CERTIFICATION						
Date of the Actual Completion of the International Search ² 10 February 1987	Date of Mailing of this International Search Report ³ <div style="text-align: center; font-size: 1.2em; font-weight: bold;">20 FEB 1987</div>					
International Searching Authority ¹ ISA/US	Signature of Authorized Officer ¹⁰ <div style="text-align: center;"> Christine M. Nucker </div>					

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
Y	Journal Of Immunological Methods, Volume 63, No. 1, issued 1983 (AMSTERDAM), R.L. RUBIN ET AL, "An Improved ELISA for Anti-Native DNA by Elimination of Interference by Anti-Histone Antibodies". (See pages 362 and 364-365).	6,13,19
Y	U.S., A, 3,720,760 (PHARMACIA AB) 13 March 1973 (13.03.73). See column 3, lines 13-30.	1-22
Y	U.S., A, 4,226,847 (MORINAGA MILK INDUSTRY CO., LTD.) 07 October 1980 (07.10.80) See Abstract.	1-22
Y	U.S., A, 4,218,335 (MOCHIDA SEIYAKU KABUSHIKI KAISHA) 19 August 1980 (19.08.80). See column 1, lines 48-60.	1-22